specialty lab diabetes testing

The Diabetes Monitoring Access Gap

Diabetes management requires regular blood draws. For rural patients, accessing consistent monitoring isn't easy. Here's what closing that gap requires.

The Tools Exist. Getting to Them Is the Problem.

Diabetes management isn't a mystery. The clinical tools are well-established, the monitoring protocols are clearly defined, and the tests that track disease progression work. HbA1c every three to six months tells a physician whether blood glucose control is actually working. A lipid panel catches cardiovascular risk — critical in a population where heart disease is the leading cause of death. Kidney function tests catch early diabetic nephropathy before it progresses. Microalbumin testing catches kidney involvement even earlier.

None of this requires specialty technology. None of it requires a specialist to administer. It requires a blood draw — a standard procedure that a qualified phlebotomist can complete in minutes.

And yet, for millions of patients managing diabetes in rural communities and underserved neighborhoods, getting that draw done consistently is not straightforward.

Where Prevalence and Access Problems Overlap

American Diabetes Month exists, in part, because the scale of the problem is easy to underestimate. Approximately 38 million Americans have diabetes. Another 98 million have prediabetes. The clinical monitoring challenge that represents is substantial.

What gets less attention is the geography of it.

Diabetes prevalence in rural America is consistently higher than in urban areas — driven by higher obesity rates, lower preventive care utilization, limited access to fresh food, and sedentary work patterns. Rural counties in the Southeast, Appalachia, and the rural Midwest have some of the highest diabetes rates in the country.

These are also the counties where specialty collection infrastructure is thinnest. Hospital outpatient labs serve the county seat. Independent draw sites, if they exist, may not be accessible to patients without transportation. Mobile collection is rarely available.

The result is a monitoring access gap that compounds a chronic disease management problem: patients who need regular blood draws to monitor a serious condition are living in communities where getting those draws done consistently requires more effort than many patients can realistically sustain.

What Consistent Monitoring Actually Looks Like

A well-controlled type 2 diabetic patient's standard monitoring schedule typically includes:

  • HbA1c every 3-6 months

  • Annual comprehensive metabolic panel (kidney function, liver enzymes, electrolytes)

  • Annual lipid panel

  • Annual urine albumin/creatinine ratio for kidney disease screening

  • Additional panels as clinical status changes

For patients managing diabetes alongside cardiovascular disease — which is common — advanced cardiovascular risk testing adds to that draw schedule. Labs like Boston Heart Diagnostics run panels that give physicians molecular-level insight into cardiovascular risk in exactly this population: the diabetic patient where cardiac risk is the most clinically important thing to understand.

The collection requirement for all of it is the same. A qualified, trained phlebotomist. A standard blood draw. A properly handled and shipped specimen. Nothing that couldn't be done at a draw site within a few miles of where the patient lives — if a draw site existed there.

What Closing the Gap Requires

Closing the diabetes monitoring access gap doesn't require building hospitals or recruiting specialists to rural communities. It requires building collection infrastructure: qualified, trained MAPs in the communities where diabetic patients live, with the coverage and reliability to make consistent monitoring practically possible.

For the patient who lives 30 minutes from the nearest draw site, the question isn't whether their physician ordered the test. The question is whether they actually complete the draw on the day it's scheduled — or whether they defer it to next month, and the month after that.

MOMS builds the collection infrastructure that reduces that barrier. Active MAPs in rural counties, smaller MSAs, and underserved communities across all 50 states, connected to the specialty labs whose tests those patients need.

The Commercial Reality for Specialty Labs

The commercial dimension of the access gap isn't complicated. Ordered volume that doesn't result in completed draws is lost revenue and incomplete patient records. For specialty labs whose clinical value depends on longitudinal monitoring — trends in HbA1c, cardiovascular risk markers, kidney function over time — the draw that doesn't happen is a gap in the evidence base that makes the test valuable in the first place.

Labs building collection infrastructure in the communities where their patients are concentrated are protecting the clinical integrity and commercial value of their test at the same time. The ones that aren't are absorbing both gaps — quietly, at the ordering physician relationship level, draw by draw.

This American Diabetes Month: the test is only as useful as the draw site that makes it accessible.

View the MOMS MAP Network coverage — active MAPs across all 50 states, including rural and underserved communities ➡️ https://www.myonemedicalsource.com/map-network-coverage

 

Similar posts

The MOMS blog features industry topics, Lab/Client partners, MOMS announcements and more.